Enzyme-Activated Antagonists of the Strychnine-Insensitive Glycine/NMDA Receptor

Francesco G. Salituro,* Ronald C. Tomlinson, Bruce M. Baron, Michael G. Palfreyman, and Ian A. McDonald[†]

Marion Merrell Dow Research Institute, 2110 East Galbraith Road, Cincinnati, Ohio 45215

Werner Schmidt, Hui-Qiu Wu, Paolo Guidetti, and Robert Schwarcz

Maryland Psychiatric Research Center, P.O. Box 21247, Baltimore, Maryland 21228

As the physiological importance of the NMDA receptor complex is being unraveled,[1-3] the search for selective modulators has attracted considerable attention in recent years.[4] Potent and selective antagonists recently have been reported for the PCP, glutamic acid, and glycine binding sites[4] which are an integral part of the NMDA receptor complex. Whereas a considerable amount of animal pharmacology has been reported on PCP-like compounds (e.g., MK 801[5]) and competitive glutamate antagonists (e.g., CPP[6], MDL 100,453[7]), relatively few reports have dealt with the glycine-site antagonists due, in part, to problems of brain penetrability. In our attempts to develop therapeutically useful agents acting at the glutamic acid[7,8] and glycine[9,10] binding sites, and to address the bioavailability problem, we have directed some of our efforts to the design of site-selective, glycine antagonists.

Kynurenic acid (3) is an endogenous broad spectrum antagonist at the ionotropic excitatory amino acid receptors in the brain, with micromolar affinity for the glycine/NMDA site.[11-14] Compound 3 may, therefore, modulate NMDA receptor function preferentially and play a role in NMDA receptor-mediated pathological processes. Indeed, exogenously applied 3[15,16] and analogues thereof[17,18] have anticonvulsant and neuroprotective properties, though their central potency is limited by their poor access to the brain.[19] The present set of experiments was designed to examine if the more potent and more receptor-specific kynurenic acid derivatives 7-chloro- (4)[20] and 5,7-dichlorokynurenic acid (5)[21] can be produced by the action of kynurenine aminotransferase, the enzyme which is singularly responsible for the biosynthesis of 3 from L-kynurenine (1) in the brain[22] (Scheme 1). Like L-kynurenine,[23] but in contrast to 3,[19] the putative bioprecursors of 4 and 5, L-4-chlorokynurenine (6) and L-4,6-dichlorokynurenine (7), may possibly cross the blood–brain barrier[19] prior to their transamination to the glycine antagonists 4 and 5. The utilization of endogenous enzymes to convert bioprecursor molecules to their active form has previously been described by McDonald et al. for the enzymatic production of a series of MAO inhibitors.[24,25]

The syntheses of analogues 6 and 7 were synthetically challenging due in large part to the difficulty in the synthesis of the requisite[26] protected arylstannanes (12 and 13) (Scheme 2). Commercially available 2-nitro-4-

---

* Author to whom correspondence should be addressed. Present address: Vertex Pharmaceuticals, 40 Allston Street, Cambridge, MA 02139-4211.
† SIBIA, 505 Coast Boulevard South, La Jolla, CA 92037.

A

B

Figure 1. Enzymatic conversion of the kynurenine derivatives 6 (300 pmol; panel A) and 7 (500 pmol; panel B) to the kynurenic acids 4 and 5, respectively. After incubation of crude rat cerebral cortex tissue homogenate for 120 min at 37 °C with 6 or 7, the supernatant was applied to a Dowex 50W column (0.5 × 1.0 cm; H⁺ form) and the kynurenic acid (KYNA) derivatives were eluted with distilled water.[22] After lyophilization, the samples were resuspended in about 100 μL of distilled water and applied to a 5 μM C₁₈ HPLC column (4.6 × 150 mm, Beckman) whereupon the amount of 4 and 5 could be quantitatively measured. Elution conditions: 4 was eluted isocratically with a mobile phase consisting of NH₄OAc (100 mM), pH 4.0, and 10% CH₃CN at a flow rate of 1.2 mL/min; spectrophotometric detection at 340 nm; retention time was approximately 7.7 min; 5 was eluted under the same conditions, but at a flow rate of 1.8 mL/min; retention time was about 14.0 min. Panel A: Production of 4 from 6: (a) heat-deactivated blank sample; (b) enzymatic product; (c) standard 4 (100 pmol). Panel B: Production of 5 from 7: (a) heat-deactivated blank sample; (b) enzymatic product; (c) standard 5 (40 pmol).

chloroaniline (8) was converted to the iodide (10) in four steps in 82% overall yield. Direct iodination of 3,5-dichloroaniline (9), followed by amine protection, afforded iodide 11 (36%). Conversion of 10 and 11 to the stannanes 12 and 13, respectively, required special conditions in order to eliminate intramolecular protonolysis. Thus, addition of a THF solution of 10 to a suspension of NaH in THF at 0 °C prior to metal–halogen exchange (*tert*-butyllithium, −78 °C), followed by quenching with (CH₃)₃SnCl, gave 12 in 66% yield after chromatography and recrystallization. Under similar conditions the dichloro analogue (13) was obtained in only 40% yield. However, this yield could be increased to 60% by a Pd⁰-catalyzed coupling reaction of the preformed Na salt of 11 with hexamethyldistannane. Coupling of 12 and 13 with the acid chloride 14[26] afforded 15 and 16 in 62% and 53% yield, respectively. Deprotection of 15 and 16 furnished 6 and 7 as pale yellow powders in 56% and 47% yields, respectively.[27]

L-4-Chlorokynurenine (6) and L-4,6-dichlorokynurenine (7) were found to be good substrates for crude rat cerebral cortex kynurenine aminotransferase and spontaneously cyclized to 4 and 5, respectively (Figure 1). Compounds 6 and 7 were independently incubated at 37 °C for 2 h


Scheme 1

1. $R^1, R^2 = H$
6. $R^1 = Cl; R^2 = H$
7. $R^1, R^2 = Cl$

2.

3. $R^1, R^2 = H$
4. $R^1 = Cl; R^2 = H$
5. $R^1, R^2 = Cl$

Scheme 2

Reaction conditions: a) 50% H_2SO_4, $NaNO_2$, $O^{\circ}C$, then KI, rt, 94%; b) Fe, HOAc, EtOH, reflux, 89%; c) di-tert-butyl dicarbonate, CH_2Cl_2, rt, R = H, 99%, R = Cl, 87%; d) K_2CO_3, EtOH, $50^{\circ}C$, R = H, 99%, R = Cl, 91%; e) N-iodosuccinimide, $HOAc/CH_2Cl_2$ (1/1), rt, 45%; f) NaH, tert-butyllithium, $(CH_3)_3SnCl$, THF, $-78^{\circ}C$, 66% (12), 40% (13); g) NaH, $(CH_3)_3Sn-Sn(CH_3)_3$, $Pd(CH_3CN)_2Cl_2$, NMP, reflux, 57% (12), 60%(13); h) 14, $Pd(CH_3CN)_2Cl_2$, toluene, reflux, 62% (15), 53% (16); I) HBr, HOAc, 30 min ; j) propylene oxide, isopropanol, RT, 56% (6), 47% (7)

14

6. R = H
7. R = Cl

with a crude enzyme preparation from rat cerebral cortex. HPLC analysis of the assays run against heat-deactivated controls and the standard products (compounds 4 and 5) confirmed the conversions. Further studies were performed with partially purified enzyme and analog 6 (Figure 2), the better of the two substrates. Thus, using standard Michaelis–Menten kinetics, conversion of 1 to 3 was shown to be competitively inhibited by 6, indicating competition of the compound with L-kynurenine for the active site of the enzyme. In addition, HPLC analyses of competing substrate reactions as described in the literature showed

that the V/K values for the two substrates were essentially equal (0.23 and 0.27 for 1 and 6, respectively).[28]

To ascertain whether 6 could be similarly metabolized in the brain *in vivo*, 6 (10 mM) was administered to the brain for 7 h via microdialysis probes positioned vertically

Figure 3. Production of 4 from 6, assessed by microdialysis in freely moving animals. Male Sprague–Dawley rats (200–250 g) were anesthetized with chloral hydrate (360 mg/kg, ip) and mounted in a stereotaxic frame. Guide cannulae for microdialysis probes were positioned bilaterally 1 mm below dura over the dorsal hippocampus. One day after surgery, the microdialysis probes were inserted through the guide cannulae, extending vertically throughout the hippocampi. Both hippocampi were perfused through the probe for 8 h with 10 mM 6, dissolved in Ringer solution, at a flow rate of 1 μL/min. In one hippocampus, 500 μM (aminooxy)acetic acid (AOAA) was added to the perfusion solution for 4 h (●), while the other hippocampus served as a control (O). Samples were collected every 60 min. Data represent the mean ± SEM of four animals. The amount of 4 (7-Cl-KYNA) formed was determined by HPLC using a 5-μm C_{18} column (4.6 × 100 mm, esa) and a mobile phase containing 50 mM NH_4OAc and 5% methanol at a flow rate of 0.5 mL/min, and spectrophotometric detection at 340 nm (retention time of 4: approximately 7.5 min). Two-way ANOVA with Newman-Keul posthoc analysis revealed a significant effect of the (aminooxy)acetic acid treatment [F (4,24) = 15.96, $P < 0.01$].

Figure 2. Kinetic analysis of the effect of 6 on partially purified rat brain kynurenine aminotransferase. The protein was purified[31] and its activity was determined in 5 μL of the enzyme preparation (54 pmol/h) as described previously.[22] Kinetic analysis was performed using different concentrations of L-kynurenine (2 μM to 2 mM) in the absence (O) or presence of 50 μM (▲) or 200 μM (●) 6. The data were analyzed by fitting two rectangular hyperbola according to the Michaelis equation using a computerized least-square fit method and represented as double-reciprocal plots.

through both dorsal hippocampi of male Sprague–Dawley rats. After 4 h, the nonspecific transaminase inhibitor, (aminooxy)acetic acid,[30] was added to the perfusion medium in one hippocampus. The production of **4** was detected within 1 h, and the levels increased until a steady state was reached at about 3 h (Figure 3). Within 1 h after the introduction of (aminooxy)acetic acid (AOAA), the concentration of extracellular **4** decreased to 23% of the control side after an additional 3 h.

Taken together, these experiments demonstrate that minor variations to the L-kynurenine structure are tolerated by brain kynurenine aminotransferase and that spontaneous cyclization of the putative keto intermediates leads to chlorine-substituted kynurenic acid derivatives which are among the most potent glycine antagonists known to date.[32] We are currently evaluating the bioavailability, pharmacological profile, and efficacy of compounds **6** and **7** in a number of biochemical and pharmacological models.

Supplementary Material Available: Experimental data for compounds mentioned in this paper (6 pages). Ordering information is given on any current masthead page.

References

(1) McCulloch, J. Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. *Br. J. Clin. Pharmacol.* **1992**, *34*, 106–114.

(2) Meldrum, B. S. Excitatory amino acids in epilepsy and potential novel therapies. *Epilepsy Res.* **1992**, *12*, 189–196.

(3) Rogawski, M. A. The NMDA receptor, NMDA antagonists and epilepsy therapy. *Drugs* **1992**, *44*, 279–292.

(4) Rowley, M.; Leeson, P. D. Excitatory amino acid antagonists. *Curr. Opinion Ther. Pat.* **1992**, *2*, 1201–1220.

(5) Domino, E. F.; Kamenka, J.-M. *Sigma and phencyclidine-like compounds as molecular probes in Biology*; NPP Books: Ann Arbor, MI, 1988.

(6) Davies, J.; Evans, R. H.; Herrling, P. L.; Jones, A. W.; Olverman, H. J.; Pook, P.; Watkins, J. C. CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [³H]D-AP5 binding sites on brain membranes and anticonvulsant activity. *Brain Res.* **1986**, *382*, 169–173.

(7) Whitten, J. P.; Baron, B. M.; Muench, D.; Miller, F.; White, H. S.; McDonald, I. A. (R)-4-Oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex. *J. Med. Chem.* **1990**, *33*, 2961–2963.

(8) Whitten, J. P.; Muench, D.; Cube, R. V.; Nyce, P. L.; Baron, B. M.; McDonald, I. A. Synthesis of 3(S)-phosphonoacetyl-2(R)-piperidinecarboxylic acid, a conformationally-restricted glutamate antagonist. *Biorg. Med. Chem. Lett.* **1991**, *1*, 441–444.

(9) Harrison, B. L.; Baron, B. M.; Cousino, D. M.; McDonald, I. A. 4-[(Carboxymethyl)oxyl]- and 4[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: new antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex. *J. Med. Chem.* **1990**, *33*, 3130–3132.

(10) Salituro, F. G.; Harrison, B. L.; Baron, B. M.; Nyce, P. L.; Stewart, K. T.; Kehne, J. H.; White, H. S.; McDonald, I. A. 3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site. *J. Med. Chem.* **1992**, *35*, 1791–1799.

(11) Perkins, M. N.; Stone, T. W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. *Brain Res.* **1982**, *247*, 184–187.

(12) Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. *J. Neurochem.* **1989**, *52*, 1319–1328.

(13) Turski, W. A.; Nakamura, M.; Todd, W. P.; Carpenter, B. K.; Whetsell, W. O., Jr.; Schwarcz, R. Identification and quantification of kynurenic acid in human brain tissue. *Brain Res.* **1988**, *454*, 164–169.

(14) Moroni, F.; Russi, P.; Lombardi, G.; Beni, M.; Carla, V. Presence of kynurenic acid in the mammalian brain. *J. Neurochem.* **1988**, *51*, 177–180.

(15) Germano, I. M.; Pitts, L. H.; Meldrum, B. S.; Bartkowski, H. M.; Simon, R. P. Kynurenate inhibition of cell excitation decreases stroke size and deficits. *Ann. Neurol.* **1987**, *22*, 730–734.

(16) Andine, P.; Lehmann, A.; Ellren, K.; Wennberg, E.; Kjellmer, I.; Nielsen, T.; Hagberg, H. The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection. *Neurosci. Lett.* **1988**, *90*, 208–212.

(17) Koek, W.; Colpaert, F. C. Selective blockade of N-Methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects. *J. Pharmacol. Exp. Ther.* **1990**, *252*, 349–57.

(18) Chiamulera, C.; Costa, S.; Reggiani, A. Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. *Psychopharmacology* **1990**, *102*, 551–552.

(19) Fukui, S.; Schwarcz, R.; Rapoport, S. I.; Takada, Y.; Smith, Q. R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. *J. Neurochem.* **1991**, *56*, 2007–2017.

(20) Kemp, J. A.; Foster, A. C.; Leeson, P. D.; Priestley, T.; Tridgett, R.; Iversen, L. L. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 6547–6550.

(21) Baron, B. M.; Harrison, B. L.; Miller, F. P.; McDonald, I. A.; Salituro, F. G.; Schmidt, C. J.; Sorensen, S. M.; White, H. S.; Palfreyman, M. G. Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated binding site. *Mol. Pharmacol.* **1990**, *38*, 554–561.

(22) Okuno, E.; Schmidt, W.; Parks, D. A.; Nakamura, M.; Schwarcz, R. Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. *J. Neurochem.* **1991**, *57*, 533–540.

(23) Gál, E. M.; Sherman, A. D. Synthesis and metabolism of L-kynurenine in rat brain. *J. Neurochem.* **1978**, *30*, 607–613.

(24) McDonald, I. A.; Lacoste, J. M.; Bey, P.; Wagner, J.; Zreika, M.; Palfreyman, M. G. Dual enzyme-activated irreversible inhibition of monoamine oxidase. *Bioorg. Chem.* **1986**, *14*, 103–118.

(25) Palfreyman, M. G.; McDonald, I. A.; Fozard, J. R.; Mely, Y.; Sleight, A. J.; Zreika, M.; Wagner, J.; Bey, P.; Lewis, P. J. Inhibition of monoamine oxidase selectivity in brain monoamine nerves using the bioprecursor (E)-β-fluoromethylene-m-tyrosine (MDL 72,394), a substrate for aromatic L-amino acid decarboxylase. *J. Neurochem.* **1985**, *45*, 1850–1860.

(26) Salituro, F. G.; McDonald, I. A. Facile synthesis of L-kynurenine. *J. Org. Chem.* **1988**, *53*, 6138–6139.

(27) Compound **7** gave a satisfactory combustion analysis (C, H, N); after deprotection, compound **6** was further purified by HPLC (Vydac C₁₈ radical pack 50- × 300-mm column, 15–20 μM. Elution: isocratic 10% CH₃CN in 0.1% TFA/H₂O).

(28) V/K values were determined from competitive substrate experiments as described in Fersht, A. *Enzyme Structure and Mechanism*, 2nd ed.; W. H. Freeman and Co.: New York, p 112. Experimental details are described in the supplementary material.

(29) Swartz, K. J.; Matson, W. R.; MacGarvey, U.; Ryan, E. A.; Beal, M. F. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. *Anal. Biochem.* **1990**, *185*, 363–376.

(30) Turski, W. A.; Gramsbergen, J. B. P.; Traitler, H.; Schwarcz, R. Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. *J. Neurochem.* **1989**, *52*, 1629–1636.

(31) Okuno, E.; Du, F.; Ishikawa, T.; Tsujimoto, M.; Nakamura, M.; Schwarcz, R.; Kido, R. Purification and characterization of kynurenine-pyruvate aminotransferase from rat kidney and brain. *Brain Res.* **1990**, *534*, 37–44.

(32) It will be important to determine to what extent compounds **6** and **7** are partitioned through other enzymatic steps of the kynurenine pathway and how these potential metabolites reflect upon the efficacy of the compounds.